Similar articles

• Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma.

  Steininger R, Herbst F, Függer R, Mühlbacher F, Fritsch A. Steininger R, et al. Transplant Proc. 1992 Dec;24(6):2690-2. Transplant Proc. 1992. PMID: 1334597 No abstract available.
• Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.

  Rizzi PM, Ryder SD, Ramage JK, Gane E, Karani J, Heaton N, Portmann B, Tan KC, Williams R. Rizzi PM, et al. Transplant Proc. 1994 Dec;26(6):3568-9. Transplant Proc. 1994. PMID: 7527979 Clinical Trial. No abstract available.
• Pattern of recurrence of hepatocellular carcinoma after liver transplantation: Milan multicenter experience.

  Regalia E, Sansalone C, Mazzaferro V, Reggiani P, Rondinara GF, Lucianetti A, Pulvirenti A, De Carlis L, Paone G, Belli L, et al. Regalia E, et al. Transplant Proc. 1994 Dec;26(6):3579-80. Transplant Proc. 1994. PMID: 7998280 Clinical Trial. No abstract available.
• Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.

  Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Zimmerman MA, et al. Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39. Arch Surg. 2008. PMID: 18283144 Review.
• [Liver transplantation for hepatocellular carcinoma: status quo and experience in Kyushu University].

  Soejima Y, Taketomi A, Ikegami T, Yoshizumi T, Uchiyama H, Gion T, Sugimachi K, Nagata S, Maehara Y. Soejima Y, et al. Fukuoka Igaku Zasshi. 2008 May;99(5):95-101. Fukuoka Igaku Zasshi. 2008. PMID: 18788452 Review. Japanese. No abstract available.